Program
Anti-ULBP2/5/6/CD3/CD2 Trispecific T-cell Engager EVOLVE104
Its studies are mostly in Urinary Bladder Neoplasms, led by EvolveImmune United.
Furthest: phase 1, since Oct 10, 20251 company-led study, 1 open or runningNext primary completion: Jan 29, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EvolveImmune United | 11 open or running | phase 1since Oct 10, 2025 | Oct 10, 2025 | Jan 29, 2029phase 1 · NCT07217171 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2025First study: phase 1 study in Urinary Bladder NeoplasmsFirst studyNCT07217171 · 160 planned · United States
Ahead
- Jan 29, 2029Primary completion: phase 1 study in Urinary Bladder NeoplasmsNCT07217171
TargetBeta
“A trispecific T-cell engager (TCE) targeting the tumor-associated antigens (TAAs) natural-killer group 2, member D receptor protein (NKG2D or KLRK1) ligands UL16-binding protein 2, 5 and 6 (ULBP2/ULBP5/ULBP6), the T-cell surface antigen CD3, and the T-cell co-stimulatory receptor CD2, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07217171Urinary Bladder Neoplasms · United States | 1 | Recruiting | Jan 29, 2029 | 160 |
How it is read
Names in the registry
- “EVOLVE104”, 2 entries
Conditions, from the studies’ own filings
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.